论文部分内容阅读
临床应用的有关鳞状上皮癌,尤其是宫颈癌的标志物中,TA-4(SCC抗原)、CEA、TPA等有较高阳性率。CEA和TPA等是各种恶性肿瘤都出现的抗原,缺乏器官特异性。与之相比,TA-4仅鳞状上皮癌出现率高,器官特异性也高。因此,如肺癌那样,在可能发生鳞状上皮癌与腺癌等各种组织类型癌肿的场合,通过联合测定SCC抗原与CEA,可在一定程度上判定肿瘤的组织类型,SCC抗原高者为鳞状上皮癌,CEA高而SCC抗原低者为腺癌。 1977年认定TA-4为鳞状上皮癌的肿瘤标志。所谓TA-4,乃是数种亚成分群的总称,分子量为42,000～48,000,认为酸性TA-4是对肿瘤更具特征
Clinical application of the squamous cell carcinoma, especially cervical cancer markers, TA-4 (SCC antigen), CEA, TPA, etc. have a higher positive rate. CEA and TPA are all kinds of malignancies are antigens, the lack of organ-specific. In contrast, TA-4 only squamous cell carcinoma of the high incidence of organ-specific high. Therefore, as in lung cancer, when various tissue-type cancers such as squamous cell carcinoma and adenocarcinoma are likely to occur, by measuring the combination of SCC antigen and CEA, the tissue type of the tumor can be determined to a certain degree, and the high SCC antigen is Squamous cell carcinoma, high CEA and low SCC antigen are adenocarcinomas. 1977 identified TA-4 as a squamous cell carcinoma tumor marker. The so-called TA-4, is the collective name of several sub-components, the molecular weight of 42,000 ~ 48,000, that TA-4 is more acidic on the tumor more features